Evidence map›Paper›PMID 35205782›Full record

ArticleCancers2022

The Dynamics of Nucleotide Variants in the Progression from Low-Intermediate Myeloma Precursor Conditions to Multiple Myeloma: Studying Serial Samples with a Targeted Sequencing Approach.

Bénedith Oben, Charlotte Cosemans, Ellen Geerdens, Loes Linsen, Kimberly Vanhees, Brigitte Maes, Koen Theunissen, Bert Cruys, Marta Lionetti, Ingrid Arijs and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Bénedith ObenLaboratory Experimental Hematology, Department Clinical Biology, Jessa Hospital, 3500 Hasselt, Belgium.
Charlotte CosemansLaboratory Experimental Hematology, Department Clinical Biology, Jessa Hospital, 3500 Hasselt, Belgium.ORCID 0000-0001-8386-301X
Ellen GeerdensLaboratory Molecular Diagnostics, Department Clinical Biology, Jessa Hospital, 3500 Hasselt, Belgium.
Loes LinsenLaboratory Experimental Hematology, Department Clinical Biology, Jessa Hospital, 3500 Hasselt, Belgium.
Kimberly VanheesFaculty of Medicine and Life Sciences, Hasselt University, 3500 Hasselt, Belgium.
Brigitte MaesLaboratory Molecular Diagnostics, Department Clinical Biology, Jessa Hospital, 3500 Hasselt, Belgium.
Koen TheunissenDepartment Hematology, Jessa Hospital, 3500 Hasselt, Belgium.
Bert CruysLaboratory Molecular Diagnostics, Department Clinical Biology, Jessa Hospital, 3500 Hasselt, Belgium.
Marta LionettiDepartment Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy.ORCID 0000-0002-3342-9095
Ingrid ArijsFaculty of Medicine and Life Sciences, Hasselt University, 3500 Hasselt, Belgium.ORCID 0000-0002-9415-083X
Niccolò BolliDepartment Oncology and Hemato-Oncology, University of Milan, 20122 Milan, Italy.ORCID 0000-0002-1018-5139
Guy FroyenFaculty of Medicine and Life Sciences, Hasselt University, 3500 Hasselt, Belgium.ORCID 0000-0002-6671-1572
Jean-Luc RummensLaboratory Experimental Hematology, Department Clinical Biology, Jessa Hospital, 3500 Hasselt, Belgium.
Jessa Hospital · BEUniversity of Milan · ITHasselt University · BE

Funding

European Union's Horizon 2020 research and innovation program 817997Limburg Clinical Research Center (LCRC)Limburgs KankerfondsLiveALife
6 · The paper itself

Abstract

Multiple myeloma (MM), or Kahler's disease, is an incurable plasma cell (PC) cancer in the bone marrow (BM). This malignancy is preceded by one or more asymptomatic precursor conditions, monoclonal gammopathy of undetermined significance (MGUS) and/or smoldering multiple myeloma (SMM). The molecular mechanisms and exact cause of this progression are still not completely understood. In this study, the mutational profile underlying the progression from low-intermediate risk myeloma precursor conditions to MM was studied in serial BM smears. A custom capture-based sequencing platform was developed, including 81 myeloma-related genes. The clonal evolution of single nucleotide variants and short insertions and deletions was studied in serial BM smears from 21 progressed precursor patients with a median time of progression of six years. From the 21 patients, four patients had no variation in one of the 81 studied genes. Interestingly, in 16 of the 17 other patients, at least one variant present in MM was also detected in its precursor BM, even years before progression. Here, the variants were present in the pre-stage at a median of 62 months before progression to MM. Studying these paired BM samples contributes to the knowledge of the evolutionary genetic landscape and provides additional insight into the mutational behavior of mutant clones over time throughout progression.

Indexed as

monoclonal gammopathy of undetermined significancemultiple myelomaprogressionsmoldering multiple myelomatargeted sequencing

Identifiers

PMID35205782
PMCPMC8870380
OpenAlexW4213181094

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.